Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Reading Your Hormone Panel

Timing, Fasting, the Harmonized-Range Problem (Travison 2017), and How the Industry Cherry-Picks Cutoffs

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
An interpretive synthesis of laboratory tests, not a product; anchored to CDC-standardized reference methods and society guidelines.

Reference only. Not medical advice.

What can go wrong

The compounded effect of poor timing, non-standardized assays, single unconfirmed draws, and cherry-picked 'optimal' cutoffs is systematic over-diagnosis of hypogonadism in healthy men, funneling them onto lifelong, fertility-suppressing therapy. The individual tests are evidence-grade; the interpretive layer sold around them is where the harm concentrates.

This is something to take to a clinician. The Atlas can tell you what is known about reading your hormone panel in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

A hormone panel is only as good as its pre-analytics and its reference frame. Testosterone must be drawn in the early morning, fasting, and away from acute illness; a single low value should be confirmed on a second morning sample because of diurnal variation and regression to the mean. Travison et al. (2017) produced CDC-harmonized reference ranges (264-916 ng/dL, 2.5th-97.5th percentile) from 9,054 men so that a value means the same thing across labs - but that harmonization only holds for CDC-certified assays. The optimization industry exploits the gaps: it draws at convenient times, runs non-standardized methods, and swaps the guideline lower limit for 'optimal' cutoffs set near the top of the young-adult range so that most men are flagged as deficient.

Every number on the sheet is real; the story sold around them usually is not.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Framework for interpreting a full male hormone panel
  • Distinguishing guideline reference ranges from marketing 'optimal' ranges
  • Identifying pre-analytic errors that corrupt results

How it works

Testosterone follows a diurnal rhythm (morning peak, afternoon trough of ~20-25%), responds acutely to food, sleep loss, and illness, and depends on binding proteins (SHBG, albumin) and pituitary drive (LH, FSH). Reading a panel correctly means integrating these: total T interpreted with SHBG, free/bioavailable T when SHBG is abnormal, LH/FSH to localize, prolactin and estradiol (sensitive assay) when indicated, and hematocrit and PSA for TRT safety. The harmonization program exists so a number is comparable across labs and time - but only when the assay is certified and the pre-analytics are controlled.

The catch: the cutoff is the product

The industry's key lever is the reference range itself. Instead of the guideline lower limit (264 or 300 ng/dL), optimization brands promote 'optimal' targets - often 600-800+ ng/dL, near the healthy young-adult median-to-upper range - so that a man at 450 ng/dL, unambiguously normal by any society, is told he is 'suboptimal' and a candidate for therapy. Layer on convenient (non-morning) draws, non-fasting samples, non-standardized immunoassays, and single unconfirmed values, and the funnel manufactures deficiency. Travison's harmonized range was built to stop exactly this kind of cross-lab, cherry-picked comparison.

What people get wrong

  • Often saidA normal testosterone isn't 'optimal' - you should aim for the top of the range

    Actually'Optimal' ranges are marketing constructs, not guideline cutoffs. A value comfortably within the harmonized reference range is normal; there is no evidence that pushing a normal man higher improves outcomes.

  • Often saidAny lab, any time, any method gives a comparable number

    ActuallyOnly CDC-certified assays with morning, fasting, confirmed draws produce comparable, interpretable values. Convenience sampling and non-standardized methods break the comparison.

  • Often saidA single low number is a diagnosis

    ActuallyDiurnal variation and regression to the mean mean a single low value often rises on a proper repeat; both guidelines require confirmation plus symptoms.

  • Often saidThe reference range is arbitrary anyway

    ActuallyThe harmonized range comes from 9,054 men and CDC standardization - it is the opposite of arbitrary. The arbitrary numbers are the 'optimal' targets brands invent.

Who profits, and who pushes back

  • Thomas Travison, PhD

    Pushes backLead author, harmonized testosterone reference ranges (2017)

    Harmonized ranges let a testosterone value mean the same thing across laboratories - provided the assay is standardized.

  • Shalender Bhasin, MD

    Pushes backLead author, Endocrine Society guideline

    A diagnosis requires symptoms plus consistently low morning testosterone on an accurate assay - not a single number compared to a marketing target.

What we do not know

  • How many 'suboptimal' diagnoses would revert to normal under morning, fasting, confirmed, CDC-certified testing against the harmonized range?
  • Should 'optimal range' marketing claims be regulated as they diverge from society reference ranges?

At a glance

Draw timing
Early morning (before ~10 AM)
Fasting
Preferred; glucose intake transiently lowers testosterone
Confirmation
Second separate morning sample for low values
Harmonized range (Travison 2017)
264-916 ng/dL, healthy nonobese men 19-39
Standardization
Holds only for CDC HoSt-certified assays

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Reading Your Hormone Panel. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Travison et al., harmonized reference ranges, JCEM2017

    Pooled 9,054 men across four US/European cohorts to define CDC-standardized ranges (264-916 ng/dL) comparable across labs

  • Bhasin et al., Endocrine Society guideline2018

    Codified morning draw, symptom requirement, repeat confirmation, and CDC-certified assays for diagnosis

  • Mulhall et al., AUA guideline2018

    Required two early-morning measurements below 300 ng/dL for diagnosis, preferably same lab and method